Gorbec currently provides complete development, regulatory, analytical, and manufacturing services for US-based customers. The company’s future plans call for an increased capacity to develop and submit New Drug Applications (NDAs) and will require an expansion of analytical services.
In an effort to improve efficiencies and reduce costs, the company has elected to locate the new analytical facility in China. The company’s core business services, current analytical laboratory and commercial manufacturing, will remain in the US. The China facility is expected to open on May 1, 2010, but Gorbec is already working with customers who have plans to use some of the new facility’s capacity.
The Yanti facility will operate under the direction of Gorbec’s vice president of analytical chemistry, Dr Jing Chen.
Mike Gorman, founder and CEO of Gorbec, said: “We are very excited about our future and our ability to offer a GMP laboratory in China. This new location will allow us to serve our own needs as well as the needs of companies looking to develop and distribute pharmaceutical products for the Asian Market.”